- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.10. | Alpha Teknova, Inc.: Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024 | 1 | GlobeNewswire (USA) | ||
| 23.08. | Alpha Teknova, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 19.08. | Here's Why Alpha Teknova (TKNO) Underperformed in Q2 | 1 | Insider Monkey | ||
| 16.08. | Alpha Teknova stock soars to 52-week high of $4.39 | 1 | Investing.com | ||
| 15.08. | Earnings call: Teknova reports on Q2 2024 with optimistic outlook | 1 | Investing.com | ||
| 13.08. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | Alpha Teknova GAAP EPS of -$0.13 beats by $0.03, revenue of $9.6M beats by $0.02M | 1 | Seeking Alpha | ||
| 13.08. | Alpha Teknova, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | Alpha Teknova, Inc.: Teknova to Report Second Quarter 2024 Financial Results on August 13, 2024 | 1 | GlobeNewswire (USA) | ||
| 17.07. | Hedge Fund and Insider Trading News: Ray Dalio, Syquant Capital, Millennium Management, NWQ Capital Management, Nickel Digital Asset Management, Alpha Teknova Inc (TKNO), and More | 1 | Insider Monkey | ||
| 12.07. | Alpha Teknova, Inc.: Teknova Announces Closing of $15.4 Million Private Placement | 1 | GlobeNewswire (USA) | ||
| 12.07. | Alpha Teknova to raise $15.4M via private placement | 1 | Seeking Alpha | ||
| 12.07. | Alpha Teknova, Inc.: Teknova Announces $15.4 Million Private Placement | 1 | GlobeNewswire (USA) | ||
| 09.07. | Teknova announces preliminary second quarter 2024 results | 2 | Seeking Alpha | ||
| 09.07. | Alpha Teknova, Inc.: Teknova Provides Strategic Business Update and Announces Preliminary Second Quarter 2024 Results | 315 | GlobeNewswire (Europe) | Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova... ► Artikel lesen | |
| 09.07. | Alpha Teknova, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.06. | Alpha Teknova, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.05. | Earnings call: Teknova sees modest revenue growth in Q1 2024 | 1 | Investing.com | ||
| 13.05. | Alpha Teknova GAAP EPS of -$0.20 beats by $0.05, revenue of $9.3M beats by $0.68M | 1 | Seeking Alpha | ||
| 13.05. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,300 | +44,44 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,428 | +12,34 % | Defence Therapeutics Inc.: Defence Therapeutics Completes 1st Tranche of Financing | Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,950 | -2,80 % | Lesaffre strengthens its Research, Development & Innovation (RD&I) with the acquisition of Altar, a company owned by Ginkgo Bioworks | MARCQ-EN-BARŒUL, France, Oct. 7, 2024 /PRNewswire/ -- Lesaffre, a key global player in the field of fermentation and microorganisms, announces the acquisition of Altar, a French start-up... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,655 | +3,42 % | Peering Into Recursion Pharmaceuticals' Recent Short Interest | ||
| BEAM THERAPEUTICS | 24,630 | +8,03 % | Beam Therapeutics' Earnings: A Preview | ||
| ONCOLYTICS BIOTECH | 1,070 | -0,93 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study | Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study
Together, these two studies support the compelling potential of pelareorep-based... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 18,120 | +2,20 % | Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect | ||
| ASSERTIO | 1,055 | +1,44 % | Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | LAKE FOREST, Ill., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,975 | -3,93 % | SIGA Technologies Inc.: SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results | ||
| ADMA BIOLOGICS | 19,280 | +0,18 % | ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Increased by Roman Butler Fullerton & Co. | ||
| VIR BIOTECHNOLOGY | 9,340 | +1,97 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,110 | +5,34 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,400 | +0,61 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Third Quarter 2024 Financial Results | FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss... ► Artikel lesen | |
| ARVINAS | 27,010 | +2,74 % | Arvinas Inc.: Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update | - On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 - - Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented... ► Artikel lesen |
ALPHA TEKNOVA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,200 (-2,79 %) liegt der Kurs bei 6,970 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALPHA TEKNOVA INC finden Sie auf Wallstreet Online.
